Matches in Nanopublications for { ?s ?p "[High prevalence of BRAF mutations in thyroid cancer is genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP114033.RAPxnrFLKx0S5L5CRI8EP-RSZnj1RddnXhcirE5UOKaf4130_assertion description "[High prevalence of BRAF mutations in thyroid cancer is genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP114033.RAPxnrFLKx0S5L5CRI8EP-RSZnj1RddnXhcirE5UOKaf4130_provenance.
- NP114106.RAdtMdeMmN9bcwxO4U--20GZ2CKLjpy48i6_aBIqxq-AE130_assertion description "[High prevalence of BRAF mutations in thyroid cancer is genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP114106.RAdtMdeMmN9bcwxO4U--20GZ2CKLjpy48i6_aBIqxq-AE130_provenance.
- assertion description "[High prevalence of BRAF mutations in thyroid cancer is genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP198954.RAb9Fu5IMP4yCP6sGpsbAhMebNk7aXY5-Mq6jUNx7AQ6I130_assertion description "[High prevalence of BRAF mutations in thyroid cancer is genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP198954.RAb9Fu5IMP4yCP6sGpsbAhMebNk7aXY5-Mq6jUNx7AQ6I130_provenance.
- NP177311.RApbwS5wkOW5QYpaMyApf0y-zPI0NFmro3UwkvITak6n0130_assertion description "[High prevalence of BRAF mutations in thyroid cancer is genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP177311.RApbwS5wkOW5QYpaMyApf0y-zPI0NFmro3UwkvITak6n0130_provenance.
- assertion description "[High prevalence of BRAF mutations in thyroid cancer is genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP198953.RAlMeodSJdmThGEjoYduVCfennK8R9A8-QHW3hjxVwLeQ130_assertion description "[High prevalence of BRAF mutations in thyroid cancer is genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP198953.RAlMeodSJdmThGEjoYduVCfennK8R9A8-QHW3hjxVwLeQ130_provenance.
- NP177239.RAIoDQWsLCZpBM2CtHY1KLKc07ITl-jWW7LqmF9acihI8130_assertion description "[High prevalence of BRAF mutations in thyroid cancer is genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP177239.RAIoDQWsLCZpBM2CtHY1KLKc07ITl-jWW7LqmF9acihI8130_provenance.